STAT3 and non-small cell lung carcinoma: Inhibiting acetylation-facilitated STAT3 signaling could reduce the metastasis from NSCLC cells, and hence provide a potentially promising approach for the treatment of NSCLC malignancy in AKR1C1-postive patients.